-+ 0.00%
-+ 0.00%
-+ 0.00%

ORIC® PHARMACEUTICALS ANNOUNCES ENOZERTINIB (ORIC-114) LATE-BREAKING ORAL PRESENTATIONS IN EGFR ATYPICAL AND EGFR EXON 20 NSCLC AT THE ESMO ASIA CONGRESS 2025

Reuters·12/03/2025 21:01:00

Please log in to view news